PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness Sponsored By: Advancing Cancer Treatment Inherited genes may help you better understand your prostate cancer, discover new treatments, and determine whether your family is at increased risk. It is essential to learn more about how inherited genes relate to prostate cancer. PROMISE is a nationwide registry study of prostate cancer patients with inherited gene mutations. The purpose of the PROMISE registry is to learn more about the role genes play in improving outcomes for prostate cancer patients. This clinical trial plans to screen approximately 5,000 men with a prostate cancer diagnosis. This registry study will help researchers better understand how genes:
WHAT IS A REGISTRY STUDY? A registry study is an observational study used to collect uniform data to evaluate outcomes for a population defined by a disease or condition. PROMISE is a registry of prostate cancer patients with specific gene mutations. WHAT’S INVOLVED?
Those who participate should receive genetic test results in 6-8 weeks; once their genetic information is obtained, patients can make an appointment to review their results with a genetic counselor. Those men with a genetic change in one of the 30 genes tested will be invited to continue participating in PROMISE through online surveys every six months. With the participant's approval, their doctor will be asked to provide information on the participant's treatment and care. PROMISE will send patients newsletters that include updates on clinical trials, new treatment options, and updates on the PROMISE research. WHO CAN PARTICIPATE?
POSSIBLE PATIENT BENEFITS:
POSSIBLE PATIENT RISKS:
TRIAL CONTACTS AND LOCATIONS:
ORGANIZATION: Prostate Cancer Clinical Trials Consortium (PCCTC) Use the “clinical trials glossary” and “dictionary” for words, phrases, and treatments that you may not understand.
|
![]() ![]() ![]() ![]() ![]() ![]() |